Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing

通过下一代蛋白A色谱技术，扩展了下游纯化产品组合，以实现可扩展的生产。

Integrated downstream workflows to improve productivity and help speed access to critical therapies

整合下游工作流程以提高生产力并帮助加速获得关键疗法

Merck, a leading science and technology company, today announced that it has successfully closed the acquisition of the chromatography business of JSR Life Sciences.

默克公司，一家领先的科技公司，今天宣布已成功完成对JSR生命科学公司的色谱业务的收购。

The acquisition adds Amsphere™ Protein A resins and advanced Protein A chromatography capabilities to Merck’s downstream processing portfolio, enabling efficient, scalable purification of monoclonal antibodies. Combined with Merck’s established downstream portfolio, these capabilities help customers improve productivity and support reliable manufacturing from development through commercial scale..

此次收购为默克的下游处理产品组合增添了Amsphere™ Protein A树脂和先进的Protein A层析能力，能够实现单克隆抗体的高效、可扩展纯化。结合默克现有的下游产品组合，这些能力帮助客户提高生产力，并支持从开发到商业规模的可靠生产。

“This acquisition expands our downstream purification capabilities at a time when customers are pushing to scale biologics faster and more efficiently,” said Sebastián Arana, Head of Process Solutions, Life Science business of Merck. “With expanded Protein A offerings, we can help customers strengthen process consistency, support reliable manufacturing at scale, and ultimately accelerate access to critical therapies.”.

“此次收购扩展了我们的下游纯化能力，而此时客户正致力于更快、更高效地扩大生物制品规模，”默克生命科学业务部工艺解决方案主管塞巴斯蒂安·阿兰纳表示。“通过扩展的Protein A产品系列，我们可以帮助客户加强工艺一致性，支持大规模的可靠生产，并最终加速获得关键疗法。”

With the acquisition, Merck adds a Belgium-based chromatography team of more than 50 employees that supplies chromatography solutions to pharmaceutical and biotech manufacturers worldwide. The team brings strong technical support and application know-how that will further strengthen Merck’s downstream offering for antibody purification.

通过此次收购，默克新增了一支位于比利时的色谱团队，该团队由50多名员工组成，为全球制药和生物技术制造商提供色谱解决方案。该团队带来了强大的技术支持和应用知识，这将进一步加强默克在抗体纯化方面的下游产品供应。

The chromatography business will be integrated into Merck’s Process Solutions portfolio, which supports customers across biopharmaceutical manufacturing from process development to full-scale manufacturing..

色谱业务将被整合到默克的过程解决方案组合中，该组合支持生物制药制造客户从工艺开发到全面生产的各个环节。